Bopriva is an anti-GnRF vaccine for use in post-pubertal non-breeding bulls.
Bopriva works by inhibiting GnRF (Gonadotropin Releasing Factor), to temporarily reduce testosterone levels for approximately three to four months. This results in decreased sexual and aggressive behaviours and easier management of bulls
Bopriva is indicated for the reduction of testosterone blood levels in post-pubertal bulls for a minimum of 12 weeks. Bopriva is prepared from an analogue of GnRF linked to a carrier protein. It is adjuvanted with a synthetic aqueous adjuvant to increase the level and duration of immunity. Each mL of vaccine provides 400 μg GnRF-protein conjugate. Thiomersal 0.1 mg/mL has been added as a preservative.
- Bopriva is a technological breakthrough in the control of sexual and/or aggressive behaviour in cattle.
- Reduced testosterone levels may result in improvements with the following behaviours: fighting; sexual mounting; pawing; digging and pasture damage; bellowing; damage to infrastructure; dominance and territorial behaviour.
- Bopriva provides farmers with more grazing management options and helps to manage larger mobs of bulls in close confinement, providing savings in time and labour.
- Bopriva contains no genetically modified organisms or artificial growth promotants and has a nil meat withdrawal period.
Bopriva is currently available in 50mL plastic multidose containers.
For subcutaneous use in the anterior half of the neck.
Primary Dose: The primary dose of 1 mL should be administered at least 3 weeks prior to the second dose i.e. at least 4-5 weeks before the desired onset of effect.
Second Dose: The second dose of 1 mL is given at least 3 weeks after the primary dose i.e. 1-2 weeks before the desired onset of effect.
Following the second vaccination there is a lag of approximately 9 days until maximum testosterone suppression. It is recommended to wait at least 10 days before mobbing groups of unfamiliar bulls together.
Altering the interval between doses is expected to alter the duration of effect. Vaccination intervals of 3-4, 6, 8 or 12 weeks are expected to provide 12, 14, 16 or up to 20 weeks of testosterone suppression respectively. (Timings are approximate only, individual and mob results will vary).
Transient swelling may be noted at the site of injection, which gradually resolves within a few weeks.
Store between 2° and 8°C (Refrigerate. Do not freeze). Protect from light.
Withholding period: Nil
Not for use in breeding stock. Correct vaccination procedure is important. Accidental vaccination of breeding stock of either sex may affect subsequent fertility.
Accidental self-injection may cause infertility in both men and women, adversely affect pregnancy or cause atrophy of sexual organs. Not to be administered by women who may be pregnant. Care should be taken to avoid accidental self-injection and needle-stick injury when administering this product. Using a safety vaccinator is recommended. In the event of accidental self-injection, seek medical advice immediately and do not administer the product in the future.
Zoetis New Zealand Limited. Level 3, 14 Normanby Road, Mt Eden, Auckland 1024, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. BOPRIVA is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A9931. RVM; Available only under Veterinary Authorisation.
For technical enquiries please phone Zoetis Technical Services on 0800 650277.